If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Schrodinger Inc. (SDGR)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are transforming the way therapeutics and materials are discovered. Their differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, they believe, a higher likelihood of success compared to traditional methods. Their software is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world, and they are the leading provider of computational software solutions for drug discovery. They also apply their computational platform to a broad pipeline of drug discovery programs in collaboration with biopharmaceutical companies, some of which they co-founded. In addition, they are using their platform to advance a pipeline of internal, wholly-owned drug discovery programs. They offer their customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2018, all of the top 20 pharmaceutical companies, measured by revenue, licensed their solutions, accounting for $22.0 million, or 33%, of their 2018 revenue. The widespread adoption of their software, supported by their global team of sales, technical, and scientific personnel, has driven steady growth in their software revenue. Biopharmaceutical companies are increasingly adopting their software at a larger scale, and they anticipate this scaling-up will drive future revenue growth.
Ramy Farid Joel Lebowitz
Employees Founded
392 1990


Address: 120 West 45th Street, 17th Floor, New York, NY 10036, US

Telephone: (212) 295-5800

Web page:

IPO information

Expected Date 2/6/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $893.5
Revenues (MM) $77.2
Net Income (Loss) (MM) $-24.2


What do you think will happen with the SDGR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 11.9
Expected offer amount (MM) $150
Realized offer amount(MM) $202.3
Morgan Stanley/ BofA Securities/ Jefferies/ BMO Capital Markets

Sector: Healthcare

Tweets about $SDGR

Tweets volume:

RT volume:


Google Trends Stats